Trials / Completed
CompletedNCT02900027
Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides
Placebo-Controlled, Dose-Escalation Study to Assess Safety, Tolerability, PK and PD of a GalNAc3 Conjugated Antisense Oligonucleotide Targeting ApoC-III, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APOC-III-LRx given to healthy volunteer subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APOC-III-L-Rx | Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection |
| DRUG | Placebo Comparator | Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-04-30
- Completion
- 2018-04-30
- First posted
- 2016-09-14
- Last updated
- 2018-05-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02900027. Inclusion in this directory is not an endorsement.